|
|
Volumn 338, Issue , 2009, Pages
|
|
Should NICE's threshold range for cost per QALY be raised? No.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DRUG;
COST BENEFIT ANALYSIS;
DRUG COST;
ECONOMICS;
HEALTH CARE COST;
HUMAN;
NATIONAL HEALTH SERVICE;
NOTE;
PRIMARY HEALTH CARE;
QUALITY ADJUSTED LIFE YEAR;
UNITED KINGDOM;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
GREAT BRITAIN;
HEALTH EXPENDITURES;
HUMANS;
PHARMACEUTICAL PREPARATIONS;
PRIMARY HEALTH CARE;
QUALITY-ADJUSTED LIFE YEARS;
STATE MEDICINE;
|
|
EID: 59049097511
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.b185 Document Type: Note |
|
Times cited : (33)
|
|
References (0)
|
